Cargando…

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)

OBJECTIVE: Abiraterone acetate has been approved in >70 countries for chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Efficacy and safety of abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily) in chemotherapy-naïve Japanese patients with meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsubara, Nobuaki, Uemura, Hirotsugu, Satoh, Takefumi, Suzuki, Hiroyoshi, Nishiyama, Tsutomu, Uemura, Hiroji, Hashine, Katsuyoshi, Imanaka, Keiichiro, Ozono, Seiichiro, Akaza, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243579/ https://www.ncbi.nlm.nih.gov/pubmed/25320340 http://dx.doi.org/10.1093/jjco/hyu149

Ejemplares similares

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
por: Yamada, Yoko, et al.
Publicado: (2016)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study
por: Suzuki, Hiroyoshi, et al.
Publicado: (2020)

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide
por: Kumano, Yohei, et al.
Publicado: (2019)

Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study
por: Koroki, Yosuke, et al.
Publicado: (2021)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
por: Eto, Masatoshi, et al.
Publicado: (2014)

Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
por: Uemura, Hiroji, et al.
Publicado: (2021)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
por: Nakayama, Masahiko, et al.
Publicado: (2016)

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients
por: Nakayama, Kazuhiro, et al.
Publicado: (2020)

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Management strategy for acute pancreatitis in the JPN Guidelines
por: Mayumi, Toshihiko, et al.
Publicado: (2006)

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2016)

A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
por: Suzuki, Kazuhiro, et al.
Publicado: (2014)

Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment
por: Uemura, Hiroji, et al.
Publicado: (2016)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

JPN Guidelines for the management of acute pancreatitis:surgical management
por: Isaji, Shuji, et al.
Publicado: (2006)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

Erratum to: Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment
por: Uemura, Hiroji, et al.
Publicado: (2017)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Early pathogenesis of the foot-and-mouth disease virus O/JPN/2010 in experimentally infected pigs
por: YAMADA, Manabu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bjcicttqmn1m9tie6otqf23fqq